

coffee conversations

EXPLORING HCV TREATMENT IN THE RAPIDLY CHANGING MEDICAID LANDSCAPE

LEARNING OBJECTIVES

- + **DISCUSS** managing HCV in your Medicaid patients
- + **EXPLORE** demonstrated efficacy and safety of MAVYRET

THIS IS MORE THAN YOUR AVERAGE WEBINAR



ENGAGING

Deep, interactive clinical discussion



SMALL GROUP DISCUSSION

Attendance is limited to 12



VIRTUAL OPPORTUNITY

Chance to interact with your peers through video

Take advantage of this opportunity to directly engage with an expert.



ELAINE (LEIGH) ENGELSMAN, DNP, FNP-BC

Doctor of Nursing Practice/Nurse Practitioner, Mercy Health Hepatitis C Clinic/McClees Clinic, Muskegon, MI



DATE & TIME

Wednesday, June 30, 2021
12:15 PM ET 11:15 AM CT
10:15 AM MT 9:15 AM PT



LOCATION

WEBINAR



PLEASE RSVP BY

June 30, 2021

abbvie.meintl.com/HCC05-HT30-21

INDICATION

MAVYRET is indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both.

Please see additional Important Safety Information on next page.
Please see accompanying full [Prescribing Information](#) or at www.rxabbvie.com/pdf/mavyret_pi.pdf.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV: Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with MAVYRET. HBV reactivation has been reported in HCV/HBV coinfecting patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfecting patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.

IMPORTANT SAFETY INFORMATION (CONT.)

CONTRAINDICATIONS

- MAVYRET is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C) or those with any history of prior hepatic decompensation.
- MAVYRET is contraindicated with atazanavir or rifampin.

WARNINGS AND PRECAUTIONS

Risk of Hepatic Decompensation/Failure in Patients with Evidence of Advanced Liver Disease

- Postmarketing cases of hepatic decompensation/failure, some fatal, have been reported in patients treated with HCV NS3/4A protease inhibitor-containing regimens, including MAVYRET. The median time to onset for MAVYRET was 27 days. The majority had moderate or severe hepatic impairment prior to initiating therapy, including some with compensated cirrhosis at baseline but with a prior decompensation event. Rare cases were reported in patients without cirrhosis or with compensated cirrhosis; many of these patients had evidence of portal hypertension. In patients with compensated cirrhosis or evidence of advanced liver disease, perform hepatic laboratory testing as clinically indicated; and monitor for signs and symptoms of hepatic decompensation such as the presence of jaundice, ascites, hepatic encephalopathy, and variceal hemorrhage. Discontinue MAVYRET in patients who develop evidence of hepatic decompensation/failure.

Risk of Reduced Therapeutic Effect Due to Concomitant Use of MAVYRET with Certain Drugs

- Carbamazepine, efavirenz, and St. John's Wort may significantly decrease plasma concentrations of glecaprevir and pibrentasvir, leading to reduced therapeutic effect of MAVYRET. The use of these agents with MAVYRET is not recommended.

ADVERSE REACTIONS

Most common adverse reactions observed with MAVYRET:

- >10% of subjects: headache and fatigue

Please see additional Important Safety Information, including **BOXED WARNING** on Hepatitis B reactivation, on previous page.

Please see accompanying full [Prescribing Information](#) or at www.rxabbvie.com/pdf/mavyret_pi.pdf.

Reference:

MAVYRET [package insert]. North Chicago, IL: AbbVie Inc.; 2020.



MAVYRET
glecaprevir/pibrentasvir
100 mg/40 mg tablets